Fundamental Analysis of NeuBase Therapeutics Inc - Growth / Value Index
NBSE - Valuation Highlights
Valuation Analysis
Price to Book Ratio is 0.0209 indicating that it is undervalued.
Tsr Value Index - Poor Score of 28.57
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -0.0233 | -0.0182 | 10.50 % | |
| Price to Book | 0.0209 | 0.0265 | 177.38 % | 0.0001 |
| Price to Sales | 0 | 0 | 0 % | |
| Enterprise Value to EBITDA Multiple | 1.43 | 0.673 | -67.26 % |
NBSE - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Very Poor Score of 5.00
Piotroski F Score - Very Poor Value of 1.0
Negative Net profit for last two years
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -89.59 | -145.64 | -209.91 % | -19.93 |
| Return On Asset | -56.60 | -103.31 | -160.90 % | -9.78 |
| Net Profit Margin | 0 | 0 | 0 % | 0 |
| Operating Profit Margin | 0 | 0 | 0 % | 0 |
| EBITDA Margin | 0 | 0 | 0 % | 0 |
Highlights
| Market Cap | 1418.10 K |
| Enterprise Value | -21073.86 K |
| Price/Book TTM | 0.0209 |
| Outstanding Share | 3751.59 K |
| Float/ Outstanding Share | 87.99% |
| Dividend Yield | 1.74 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 1.00 |
| Altman Z Score | -6.97 |
| Sloan Ratio | -0.131 |
| Peter Lynch Fair Value | 0 |
NBSE - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Quarterly sales in last 5 Quarter is trending down
Annual sales in last 3 years is trending down
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | NA | % | % |
| Gross Profit | -854694.00 | 119.37 % | 17.68 % |
| EBITDA | -14713.92 K | 29.76 % | 23.72 % |
| Net Profit | -13661.24 K | 32.93 % | 47.17 % |
| EPS | -16.19 | 11.73 % | NA |
NBSE - Stability Highlights
Stability Analysis
Cash ratio of 5.56
Altman Z Score of -6.97 suggest high risk
Company is unable to generate enough free cash to support the business.
Interest Coverage of -1403.60
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0285 | 76.49 % | 0.055 |
| Cash Ratio | 5.56 | -55.94 % | |
| Quick Ratio | 5.95 | 0 % | 2.87 |
| Shareholders Equity | 70.94 | -15.81 % | |
| Debt to EBITDA | -0.0203 | 41.66 % |
Historical Valuation Ratios of NeuBase Therapeutics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of NeuBase Therapeutics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of NeuBase Therapeutics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of NeuBase Therapeutics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)